MTOR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Additionally, the therapeutic benefits of mTOR inhibitors have been demonstrated in a patient with Xp11.2 tRCC who did not show a favorable response to first-line VEGF inhibitor treatment [21].